RT Journal Article
SR Electronic
T1 Bradycardia associated with pegylated liposomal doxorubicin administration: a case report
JF European Journal of Hospital Pharmacy
JO Eur J Hosp Pharm
FD British Medical Journal Publishing Group
SP 128
OP 130
DO 10.1136/ejhpharm-2015-000817
VO 24
IS 2
A1 Zhaolu Xie
A1 Wei Wu
A1 Haiyan Xing
A1 Yongqing Cai
A1 Xianfeng Wang
A1 Jianhong Chen
YR 2017
UL http://ejhp.bmj.com/content/24/2/128.abstract
AB The cardiotoxicity of doxorubicin is dose dependent and progressive, but its mechanisms remain unclear. Measures to prevent the cardiotoxicity of doxorubicin have had limited success. We report here on a patient who had received intravenous infusion of pegylated liposomal doxorubicin and developed sinus bradycardia despite the prior administration of the iron-chelating agent, dexrazoxane. The adverse effect of pegylated liposomal doxorubicin might be due to the difference in metabolic related genes for anthracyclines. Therefore, monitoring the cardiac condition of patients who receive doxorubicin treatment, even at low doses, is highly recommended.